Literature DB >> 16510768

Valproic acid adjunctive therapy for HIV-associated cognitive impairment: a first report.

G Schifitto1, D R Peterson, J Zhong, H Ni, K Cruttenden, M Gaugh, H E Gendelman, M Boska, H Gelbard.   

Abstract

In vitro and animal model data demonstrate that valproic acid (VPA) can ameliorate HIV-associated neurotoxicity. The authors conducted a pilot 10-week placebo-controlled study of VPA 250 mg twice daily in 22 HIV-infected individuals with (n = 16) and without (n = 6) cognitive impairment. VPA was safe and well tolerated, with trends toward improved neuropsychological performance and brain metabolism in the impaired subjects.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16510768     DOI： 10.1212/01.wnl.0000204294.28189.03

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


  46 in total

Review 1.  Editorial neuroAIDS review.

Authors:  Paul Shapshak; Pandjassarame Kangueane; Robert K Fujimura; Deborah Commins; Francesco Chiappelli; Elyse Singer; Andrew J Levine; Alireza Minagar; Francis J Novembre; Charurut Somboonwit; Avindra Nath; John T Sinnott
Journal:  AIDS       Date:  2011-01-14       Impact factor: 4.177

Review 2.  Brain dysfunction in the era of combination antiretroviral therapy: implications for the treatment of the aging population of HIV-infected individuals.

Authors:  Uraina S Clark; Ronald A Cohen
Journal:  Curr Opin Investig Drugs       Date:  2010-08

3.  The role of cohort studies in drug development: clinical evidence of antiviral activity of serotonin reuptake inhibitors and HMG-CoA reductase inhibitors in the central nervous system.

Authors:  Scott L Letendre; Jennifer Marquie-Beck; Ronald J Ellis; Steven Paul Woods; Brookie Best; David B Clifford; Ann C Collier; Benjamin B Gelman; Christina Marra; Justin C McArthur; J Allen McCutchan; Susan Morgello; David Simpson; Terry J Alexander; Janis Durelle; Robert Heaton; Igor Grant
Journal:  J Neuroimmune Pharmacol       Date:  2007-01-03       Impact factor: 4.147

Review 4.  Debate: "is increasing neuroinflammation beneficial for neural repair?".

Authors:  Keith A Crutcher; Howard E Gendelman; Jonathan Kipnis; J Regino Perez-Polo; V H Perry; Phillip G Popovich; Lynne C Weaver
Journal:  J Neuroimmune Pharmacol       Date:  2006-05-23       Impact factor: 4.147

5.  HIV latency: present knowledge, future directions.

Authors:  Xavier Contreras; Tina Lenasi; B Matija Peterlin
Journal:  Future Virol       Date:  2006       Impact factor: 1.831

Review 6.  A coat of many colors: neuroimmune crosstalk in human immunodeficiency virus infection.

Authors:  Stephanie D Kraft-Terry; Shilpa J Buch; Howard S Fox; Howard E Gendelman
Journal:  Neuron       Date:  2009-10-15       Impact factor: 17.173

7.  The recombinant vaccinia virus gene product, B18R, neutralizes interferon alpha and alleviates histopathological complications in an HIV encephalitis mouse model.

Authors:  Cari Fritz-French; Ramzi Shawahna; Jennifer E Ward; Leonard E Maroun; William R Tyor
Journal:  J Interferon Cytokine Res       Date:  2014-02-24       Impact factor: 2.607

8.  Effects of HIV-1 Tat on oligodendrocyte viability are mediated by CaMKIIβ-GSK3β interactions.

Authors:  Shiping Zou; Joyce M Balinang; Jason J Paris; Kurt F Hauser; Babette Fuss; Pamela E Knapp
Journal:  J Neurochem       Date:  2019-03-15       Impact factor: 5.372

9.  Isolation of a fission yeast mutant that is sensitive to valproic acid and defective in the gene encoding Ric1, a putative component of Ypt/Rab-specific GEF for Ryh1 GTPase.

Authors:  Yan Ma; Reiko Sugiura; Lili Zhang; Xin Zhou; Mai Takeuchi; Yi He; Takayoshi Kuno
Journal:  Mol Genet Genomics       Date:  2010-07-10       Impact factor: 3.291

10.  Neuroprotective activities of CEP-1347 in models of neuroAIDS.

Authors:  Dawn Eggert; Prasanta K Dash; Santhi Gorantla; Huanyu Dou; Giovanni Schifitto; Sanjay B Maggirwar; Stephen Dewhurst; Larisa Poluektova; Harris A Gelbard; Howard E Gendelman
Journal:  J Immunol       Date:  2009-12-04       Impact factor: 5.422
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.